SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing heightened volatility and intense community debate as investors react to the company's latest quarterly results and forward guidance, with discussions centering on its aggressive revenue growth targets for 2030 and its expanding role in AI-driven compute architectures. While bullish participants highlight the stock's long-term potential as a critical component in next-generation AI infrastructure, bears are aggressively questioning the company's valuation multiples and the sustainability of its rapid price appreciation.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors react to a quarterly report that beat revenue and user growth expectations but faced downward pressure due to cautious revenue guidance and the termination of a partnership. The community is actively debating the effectiveness of leadership and the company's long-term potential as a cash-flow-positive player in the AR and AI space.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is seeing high volatility and heavy trading volume as investors debate its upcoming earnings report, with bulls highlighting the company's massive revenue growth and expanding commercial backlog while bears focus on high cash burn and valuation concerns. The community is actively discussing whether the company's aggressive growth trajectory justifies its market cap or if the current price action is simply a pre-earnings speculative pump followed by an inevitable correction.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh stellar earnings and aggressive AI-driven ad revenue growth against broader software sector weakness and concerns over valuation. While bulls are encouraged by record-breaking margins and the potential for a massive breakout, others are focused on institutional profit-taking and fears of a long-term software overhang.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending as investors weigh significant revenue growth and a record backlog against concerns regarding ongoing equity distribution and capital structure. The community is actively debating whether the recent heavy institutional selling indicates a long-term fundamental shift or a temporary supply overhang that creates an entry opportunity ahead of future space sector momentum.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently experiencing heightened volatility and intense community debate as investors react to the completion of Rakuten's planned share sales and growing anticipation for the upcoming quarterly earnings report. While some investors are treating the recent price pullback as a strategic buying opportunity, others are expressing frustration over launch delays and questioning the company's ability to hit its aggressive 2026 satellite constellation targets.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing extreme volatility and intense community debate following a short seller report, with investors focused on the company's robust rebuttal and strong fundamentals, including recent label expansion news and high institutional interest. The prevailing community sentiment is split between 'buy-the-dip' conviction from long-term holders and caution surrounding potential near-term price manipulation.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant market volatility and intense community discussion following recent earnings and ongoing debates regarding Elevidys demand. Investors are actively contrasting the stock's discounted valuation against its commercialized gene therapy portfolio and pipeline potential, with many speculating on the impact of upcoming regulatory catalysts and potential buyout scenarios.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor bears are facing extreme pressure as a relentless melt-up in chip stocks continues to ignore valuation concerns and geopolitical risks. Community sentiment is deeply divided, with many traders frustrated by consistent after-hours rallies and a persistent disconnect between sector earnings and price action, leaving some to debate capitulation while others hold out for an expected correction.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is seeing intense market activity following an earnings report that highlighted record-breaking backlog and massive revenue growth, fueling a tug-of-war between optimistic investors citing data center demand and bearish traders focused on margin pressures. The community is actively debating whether the stock is undergoing a long-term structural re-rating driven by AI-powered infrastructure needs or if recent volatility represents an earnings-driven trap for retail shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026.</li><li>Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression.</li><li>Allucent will provide end-to-end support for the clinical trial, including execution and data management.</li></ul>Shares of Quantum BioPharma (QNTM) surged 15% in pre-market trading on Monday after the biotech firm signed a binding agreement with Allucent to support a planned Phase 2 trial of its Lucid-MS therapy for multiple sclerosis.The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026, Quantum BioPharma said.Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression. Allucent will provide end-to-end support for the clinical trial, including execution and data management.“This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration,” said Andrzej Chruscinski, VP, Scientific and Clinical Affairs at Quantum BioPharma.&nbsp;&nbsp;<h2 class="st-heading-2">Funding Update</h2>Earlier this month, Quantum BioPharma completed oral dosing of Lucid-21-302 (Lucid-MS) in both its 180-day toxicity and toxicokinetic studies, marking an important step toward filing an Investigational New Drug (IND) application with the U.S. FDA. The company is focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol-related disorders, with multiple drug candidates in its pipeline.Alongside clinical progress, Quantum BioPharma also strengthened its financial position by closing the first tranche of a previously announced offering, raising $3.75 million through the issuance of 3,750 debenture units.&nbsp;Additionally, the company settled about $1.12 million in debt by issuing over 370,000 Class B shares to certain creditors and insiders, helping improve its balance sheet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/QNTM">QNTM</a> remained 'bullish' over the past 24 hours, amid 'extremely high' message volumes.One user said the company's market cap should be "north of $100 million" following the developments.<stembedurl>https://stocktwits.com/TAGtrade/message/648919385</stembedurl>Year-to-date, the stock has declined 30%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did QNTM Stock Pop In Pre-Market Today?

The biotech company signed a binding agreement with Allucent to support a planned Phase 2 trial to treat multiple sclerosis.

Equity

Quantum BioPharma Targets MS Progression with Novel Demyelination Therapy in Phase 2 Push

Quantum BioPharma (NASDAQ:QNTM) is taking a meaningful step forward in its clinical ambitions, signing a binding letter of intent with Allucent to advance its lead multiple sclerosis candidate, Lucid-21-302 (Lucid-MS), into a Phase 2 trial. The agreement signals more than operational progress, it reflects a broader push to bring differentiated, next-generation therapies into a market that remains heavily underserved despite decades of innovation.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM INVESTOR ALERT: Pomerantz Law Firm...

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM CONTACT: INVESTOR ALERT...

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to...

<ul class="summary-bullets"><li>The stock surged as Canadian media spotlight renewed scrutiny of Quantum’s alleged market-spoofing case.</li><li>The coverage drew fresh attention to the company’s $700 million federal lawsuit over price manipulation.</li><li>Lucid-MS’s Phase 1 safety data in August supported advancement toward patient trials.</li></ul>Quantum BioPharma shares surged on Tuesday after a Canadian media investigation spotlighted the company’s claims that years of alleged stock spoofing depressed its valuation and harmed its lead multiple-sclerosis program. The renewed attention came as CTV’s investigative flagship W5 began airing a three-part series examining Quantum’s lawsuit seeking more than $700 million in damages.The stock closed up 30% at $8.04 on Tuesday and added another 5% in after-hours trading.<h2 class="st-heading-2">CTV Investigation Highlights Company’s Manipulation Claims</h2>The W5 series focuses on Quantum’s allegation that its shares were repeatedly manipulated through illegal “stock spoofing” conducted by CIBC World Markets, RBC Dominion Securities and others from January 2020 to August 2024. The practice, which involves placing and canceling non-bona fide buy and sell orders, is prohibited in both Canada and the U.S.W5 reporter Jon Woodward previewed the first installment in an article titled “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” The program began airing Part One on Tuesday, drawing renewed attention to Quantum’s claims and its ongoing legal fight.<h2 class="st-heading-2">Quantum Alleges Banks Used Spoofing To Drive Shares Lower</h2>Quantum filed its initial complaint in October 2024 in the U.S. District Court for the Southern District of New York and amended it in May after defendants moved to dismiss. The company alleges violations of the Securities Exchange Act, asserting that hundreds of spoofing events artificially pushed its stock lower.Quantum said its shares traded above $460 on a split-adjusted basis in early 2020 with a market cap near $1 billion, compared with $7.55 by October 2024. The firm also maintains that additional banks or brokers may have been involved, but said it will not identify them until it has gathered sufficient evidence.The law firms Christian Attar and Freedman Normand Friedland LLP are pursuing the case on a contingency basis after conducting an extensive investigation with industry experts.<h2 class="st-heading-2">Progress In Lucid-MS Program&nbsp;</h2>In August, Quantum BioPharma reported that its lead multiple sclerosis candidate, Lucid-MS, passed a key safety hurdle after a Phase 1 multiple-ascending-dose study found no safety or tolerability issues in healthy volunteers. The company said the clinical study report supported its plans to advance into patient efficacy trials.Lucid-MS is a first-in-class, non-immunomodulatory neuroprotective compound designed to prevent or reverse myelin degradation, based on preclinical data.&nbsp;<h2 class="st-heading-2">Stocktwits Users Eye A Sharp Rebound</h2>On Stocktwits, retail sentiment for Quantum BioPharma was ‘extremely bullish’ amid a 3,400% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:971/141;" src="https://news.stocktwits-cdn.com/qntm_ss_png_e73bb7bac7.webp" alt="qntm ss.png" width="971" height="141"><figcaption>QNTM sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One user predicted, “shorts will be covering tomorrow due to thanksgiving. Should see $18 soon.”<stembedurl>https://stocktwits.com/James9921/message/637453956</stembedurl>Another user said, “this one has been absolutely wrecked here but historically when the stocks this low it sees a violent move up. Watching closely here.”<stembedurl>https://stocktwits.com/makedatbread88/message/637220177</stembedurl><a href="https://stocktwits.com/symbol/QNTM">Quantum BioPharma’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Quantum BioPharma’s stock (QNTM) has more than doubled so far in 2025. (Photo credit: Getty Images)

Quantum BioPharma Stock Rockets As Media Probe Shines Light On Spoofing Allegations Linked To Its $700M Lawsuit

Lucid-MS’s Phase 1 safety data in August supported advancement toward patient trials.

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights QNTM

The DJS Law Group announces that it is investigating claims on behalf of investors of Quantum BioPharma Ltd. (Quantum BioPharma or the Company) (NASDAQ: QNTM) for violations of the securities laws...

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$5.28
Prev Close	$5.36
Open	$5.17
Dividend Yield	0.00%
50-Day Moving Average	$3.68
Beta	1.31
Avg. Volume	471,487.80
PE Ratio	-0.62

52-Week High	$38.25
52-Week Low	$2.07
Market Capitalization	$31.24M
EPS (Annual)	-$7.97
Price to Book	3.01
Revenue Per Employee	N/A

QNTM
Quantum BioPharma Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest QNTM News

QNTMQuantum BioPharma Ltd